Evidence map›Paper›PMID 38663935›Full record

ArticleJournal for immunotherapy of cancer2024

Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination.

Robert A Watson, Weiyu Ye, Chelsea A Taylor, Elsita Jungkurth, Rosalin Cooper, Orion Tong, Tim James, Brian Shine, Monika Hofer, Damian Jenkins and 9 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Cryptic late-onset myocarditis after coronavirus vaccination.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Robert A WatsonMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Weiyu YeMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Chelsea A TaylorMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Elsita JungkurthMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Rosalin CooperMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Orion TongMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Tim JamesDepartment of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Brian ShineDepartment of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Monika HoferDepartment of Neuro Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Damian JenkinsDepartment of Clinical Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Robert PellDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Eleni IeremiaDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Stephanie JonesOxford Centre for Histopathological Research, Oxford University Hospitals NHS Trust, Oxford, UK.
David Maldonado-PerezOxford Centre for Histopathological Research, Oxford University Hospitals NHS Trust, Oxford, UK.
Ian S D RobertsDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Nicholas CoupeCancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Mark R MiddletonDepartment of Oncology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-0167-1685
Miranda J PayneCancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Benjamin P FairfaxMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK benjamin.fairfax@oncology.ox.ac.uk.ORCID http://orcid.org/0000-0001-7413-5002

Funding

Cancer Research UKWellcome Trust
6 · The paper itself

Abstract

We describe three cases of critical acute myositis with myocarditis occurring within 22 days of each other at a single institution, all within 1 month of receiving the initial cycle of the anti-PD-1 drug pembrolizumab. Analysis of T cell receptor repertoires from peripheral blood and tissues revealed a high degree of clonal expansion and public clones between cases, with several T cell clones expanded within the skeletal muscle putatively recognizing viral epitopes. All patients had recently received a COVID-19 mRNA booster vaccine prior to treatment and were positive for SARS-CoV2 Spike antibody. In conclusion, we report a series of unusually severe myositis and myocarditis following PD-1 blockade and the COVID-19 mRNA vaccination.

Indexed as

Antibodies, Monoclonal, HumanizedCOVID-19MyocarditisMyositisSARS-CoV-2AgedAged, 80 and overCOVID-19 VaccinesFemaleHumansImmune Checkpoint InhibitorsMaleVaccinationAntibodies, Monoclonal, HumanizedCOVID-19 VaccinesImmune Checkpoint InhibitorspembrolizumabCase ReportsImmune Checkpoint InhibitorsMelanomaReceptors, AntigenT-Lymphocytes

Identifiers

PMID38663935
PMCPMC11043765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.